MBRX News and Press, Moleculin Biotech Inc. From 11/04/21

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast roundtable discussions with members of Management and Thought Leaders across participating companies - PITTSTOWN, NJ / ACCESSWIRE / November 4, 2021 / November 4, 2021 -...

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19 - First-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteer...

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases - Preliminary data from two cohorts evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases currently demonstrate 80% clinica...

Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference - Live webcast presentation on Monday, September 27th at 8:40 AM ET PR Newswire HOUSTON , Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or th...

Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit - Live webcast presentation on Monday, September 20th at 4:35 PM ET PR Newswire HOUSTON , Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ...

Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire HOUSTON , Sept. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad ...

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update - Continued execution of multiple ongoing clinical studies for the treatment of highly resistant tumors and viruses - - Key clinical and regulatory milestones throughout next 18 months inclu...

Shares of Moleculin Biotech Inc. (NASDAQ:MBRX) traded today at $3.10, breaking its 52-week low. This new low was reached on below average trading volume as 118,000 shares traded hands, while the average 30-day volume is approximately 281,000 shares. Moleculin Biotech Inc is a clinical-st...

Moleculin Biotech (MBRX) has received approval for a protocol amendment for its Phase 1/2 evaluating annamycin for the treatment of certain patients with acute myeloid leukemia ((AML)).The go-ahead for the amendment came from the Bioethics Committee of the Medical Universi...

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia - Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects - Demonstr...